Sells aortic repair devices, heart valves and preserved human tissues to cardiac and vascular surgeons and hospitals.
10-K for FY2025, filed Feb 18, 2026Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical…View ↗
Our medical devices and preservation services are primarily used by cardiac and vascular surgeons to treat patients with aortic disease…View ↗
We currently market the On-X aortic and mitral mechanical heart valves for valve replacement procedures. We also market our cardiac…View ↗
Customers pay for medical devices when they ship and for preservation services when tissue ships; consignment product sales are charged when Artivion is notified of implantation.
10-K for FY2025, filed Feb 18, 2026Revenues for products, including: aortic stent grafts, surgical sealants, On-X products, and other medical devices, are typically…View ↗
10-K for FY2025, filed Feb 18, 2026
FY2025 revenue by product or service ↗$441.3M
10-K for FY2025, filed Feb 18, 2026
$441.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Aortic stent grafts
Sold outright
10-K for FY2025, filed Feb 18, 2026 |
36%
FY2022: 30%
|
Aortic stent grafts, FY2025
$159.4M Sources
|
Sold outright |
|
On-X
Sold outright
10-K for FY2025, filed Feb 18, 2026 |
23%
FY2022: 20%
|
On-X, FY2025
$101.7M Sources
|
Sold outright |
|
Surgical sealants
Sold outright
10-K for FY2025, filed Feb 18, 2026 |
17%
FY2022: 21%
|
Surgical sealants, FY2025
$76.6M Sources
|
Sold outright |
|
Other
Sold outright
|
1.8%
FY2022: 2.7%
|
Other, FY2025
$8.1M Sources
|
Sold outright |
|
Preservation services
Sold outright
10-K for FY2025, filed Feb 18, 2026 |
22%
FY2022: 27%
|
Preservation services, FY2025
$95.5M Sources
|
Sold outright |
In the US and Canada, Artivion markets to physicians and sells through its direct sales team to hospitals and other healthcare facilities. In EMEA, it sells directly in some countries and through distributors in others; in APAC and Latin America, it uses distributors and subsidiaries, with direct sales also in Brazil.
10-K for FY2025, filed Feb 18, 2026In the US and Canada, we market our products and preservation services primarily to physicians and sell our products through our…View ↗
In EMEA, we market our products through our European headquarters, based in Hechingen, Germany, as well as through several other…View ↗
In APAC and LATAM, we commercialize our products through our independent distributors and our subsidiaries through approximately 50 sales…View ↗
North America: consists of US and Canada. We market our medical device products and preservation services (predominantly in the US)…View ↗
Yes. It kept 2 cents of every revenue dollar as net income in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$7.9MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Artivion is reiterating its expectations for revenue for the full year 2026 to be in the range of $480 to $496 million, representing growth…View ↗
8-K, filed May 7, 2026
Artivion has lowered its expectations for revenue for the full year 2026 and now expects revenue to be in the range of $480 to $496…View ↗
Growing. Revenue grew 48% in 4 years, from $298.8M in FY2021 to $441.3M in FY2025, about 10% a year.
CardioGenesis and PerClot
The older report listed CardioGenesis and PerClot among its products; the latest says CardioGenesis was abandoned and PerClot is manufactured and supplied under a transitional agreement.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 18, 2026Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical…View ↗
Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical…View ↗
Competes with Abbott Laboratories, Medtronic, Corcym, and Terumo
10-K for FY2025, filed Feb 18, 2026On-X heart valves compete primarily with mechanical valves from Abbott Laboratories, Medtronic, plc. (“Medtronic”), and Corcym S.r.l. (who…View ↗
Loading...